Quick Answer
Oruka Therapeutics, Inc. reported Net Income of -$105.43 million for fiscal year 2025.
Oruka Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$105.43M -25.9% |
-$83.72M -1468.2% |
-$5.34M +46.2% |
-$9.93M +48.6% |
-$19.32M -98.4% |
-$9.74M -77.6% |
| Diluted EPS | — | -$3.87 -945.9% |
-$0.37 +46.4% |
-$0.69 +50.4% |
-$1.39 | — |
| Total Assets | $488.62M +48861600.0% |
$1.0K -100.0% |
$37.86M -12.1% |
$43.09M -21.6% |
$54.92M +8.9% |
$50.43M +490.8% |
| Cash and Equivalents | $46.94M -23.8% |
$61.58M +64.5% |
$37.43M -11.8% |
$42.45M -20.5% |
$53.36M +8.7% |
$49.07M +486.8% |
| Stockholders Equity | $471.93M +47192900.0% |
$1.0K -100.0% |
$37.02M -11.2% |
$41.67M -18.4% |
$51.04M +9.7% |
$46.52M +511.3% |
| R&D Expense | $100.64M +34.1% |
$75.06M +7309.7% |
$1.01M -78.7% |
$4.75M -65.7% |
$13.83M +177.1% |
$4.99M +172.3% |
| Operating Income | -$122.05M -38.5% |
-$88.12M -1107.8% |
-$7.30M +31.1% |
-$10.60M +45.2% |
-$19.34M -98.0% |
-$9.77M -68.0% |
| Shares Outstanding | 48.72M +1423.5% |
3.20M -77.9% |
14.50M +0.6% |
14.41M +0.0% |
14.41M +50.9% |
9.55M +499.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$30.28M | -5.8% | -23.2% |
| Diluted EPS | June 30, 2025 | -$0.46 | +93.4% | -15.0% |
| Total Assets | September 30, 2025 | $509.25M | +23.0% | +42.5% |
| Cash and Equivalents | September 30, 2025 | $91.25M | -77.8% | +39.5% |
| Stockholders Equity | September 30, 2025 | $486.79M | +42.2% | +41.7% |
| R&D Expense | September 30, 2025 | $28.99M | +12.8% | +20.3% |
| Operating Income | September 30, 2025 | -$34.10M | -15.8% | -20.0% |
| Shares Outstanding | September 30, 2025 | 48.38M | +38.2% | +29.2% |
- Oruka Therapeutics, Inc. reported Net Income of -$105.43 million for fiscal year 2025.
- Oruka Therapeutics, Inc. showed a decrease of -25.9% in Net Income compared to the prior fiscal year.
- Oruka Therapeutics, Inc. reported Diluted EPS of $3.87 per share (loss) for fiscal year 2024.
- Oruka Therapeutics, Inc. showed a decrease of -945.9% in Diluted EPS compared to the prior fiscal year.
- Oruka Therapeutics, Inc. reported Total Assets of $488.62 million for fiscal year 2025.
- Oruka Therapeutics, Inc. showed an increase of +23.4% in Total Assets compared to the prior fiscal year.
- Oruka Therapeutics, Inc. reported Cash and Equivalents of $46.94 million for fiscal year 2025.
- Oruka Therapeutics, Inc. showed a decrease of -23.8% in Cash and Equivalents compared to the prior fiscal year.
- Oruka Therapeutics, Inc. reported Stockholders Equity of $471.93 million for fiscal year 2025.
- Oruka Therapeutics, Inc. showed an increase of +23.5% in Stockholders Equity compared to the prior fiscal year.
- Oruka Therapeutics, Inc. reported R&D Expense of $100.64 million for fiscal year 2025.
- Oruka Therapeutics, Inc. showed an increase of +34.1% in R&D Expense compared to the prior fiscal year.
- Oruka Therapeutics, Inc. reported Operating Income of -$122.05 million for fiscal year 2025.
- Oruka Therapeutics, Inc. showed a decrease of -38.5% in Operating Income compared to the prior fiscal year.
- Oruka Therapeutics, Inc. reported Shares Outstanding of 48.72 million shares for fiscal year 2025.
- Oruka Therapeutics, Inc. showed an increase of +30.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: